Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 17/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2274545 | 0.92 | SMO (0.81) | SMONPSR1MEN1KMT2AHTT | |
| SCHEMBL2272806 | 0.89 | SMO (0.84) | SMO | |
| SCHEMBL2277847 | 0.87 | SMO (0.67) | SMONPSR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12400961 | 0.87 | SMO (0.72) | SMONPSR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2271495 | 0.87 | SMO (0.72) | SMONPSR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2271491 | 0.87 | SMO (0.72) | SMONPSR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2278120 | 0.86 | SMO (0.66) | SMONPSR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2276591 | 0.86 | SMO (0.66) | SMONPSR1HTT | |
| Hydrochloric Acid SCHEMBL2275064 | 0.86 | SMO (0.71) | SMONPSR1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12400972 | 0.86 | SMO (0.71) | SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364185-B1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | LILLY CO ELI (US) | 2013-05-22 | — | — | EP | disclosed |
| US-8404687-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2364185-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-09-14 | — | — | EP | disclosed |
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010062507-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190304-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | SMO 3/4885NPSR1 1903/4885MEN1 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.